Objective: A new strategy for menopausal hormone therapy replaces medroxyprogesterone with the selective estrogen receptor modulator bazedoxifene. While the agonist or antagonist activity of bazedoxifene has been examined in other tissues, the current study explored the impact of bazedoxifene on resistance artery reactivity. We hypothesized that bazedoxifene may induce greater vasoprotective effects than estradiol due to enhanced activation of the G-protein-coupled estrogen receptor.
T he combination of estrogen therapy with the selective estrogen receptor modulator (SERM) bazedoxifene (BZA) is a novel progestogen-free therapy that alleviates menopausal symptoms and negates the proliferative effects of estrogen on the breast and uterus.
1,2 Activation of nuclear estrogen receptors induces a conformational shift and recruitment of coregulators to selectively alter gene transcription. 3 The expression of coregulators varies by tissue, thereby allowing tissue-specific responses to the same ligand-receptor complex. Moreover, the conformation of the estrogen receptor is important for coregulator recruitment and can be influenced by the chemical structure of the ligand. SERMs such as BZA capitalize on the unique complexity of this system to produce agonist or antagonist responses in each tissue. In addition, BZA induces the degradation of estrogen receptor alpha (ERa) via the ubiquitin proteasome system to further oppose proliferation of uterine and breast tissue. 4 In comparison with estrogen therapy, hormone therapy containing medroxyprogesterone (MPA) is associated with a higher risk of breast cancer and cardiovascular disease. 5 MPA antagonizes the protective effects of estrogen on flowmediated dilation in menopausal women 6, 7 and on atherosclerosis in ovariectomized monkeys. 8 Therefore, replacing MPA with another drug to antagonize the proliferative effects of The Selective Estrogens, Menopause, and Response to Therapy (SMART) trial shows that BZA combined with estrogen therapy for up to 2 years improves menopause-related symptoms with an acceptable cardiovascular safety profile. 11, 12 The loss of estrogens that occurs with menopause is associated with an increase in blood pressure 13 and a reduction in endothelial function. 14 Conversely, acute administration of 17b-estradiol (E 2 ) induces vasorelaxation in postmenopausal women, 15 and also in female animals. 16 Previous-generation SERMs, such as raloxifene and 4OH-tamoxifen, improve acetylcholine-induced relaxation in mesenteric arteries from ovariectomized female Wistar rats 17 and stimulate nitric oxide production to a similar extent as E 2 in cultured endothelial cells. 18 In postmenopausal women, raloxifene treatment significantly increases brachial artery flow-mediated dilation compared with placebo. 6, 14 These studies indicate that SERMs may provide similar vascular benefits as E 2 . However, whether the substitution of MPA with BZA in hormone therapy is beneficial for the vasculature remains to be determined.
Estrogen receptors alpha and beta (ERa/ERb) and the Gprotein-coupled estrogen receptor (GPER) are expressed in endothelial and vascular smooth muscle cells, and contribute to vascular tone. 19, 20 SERMs are commonly characterized according to their impact on nuclear ER activation, but SERMs such as tamoxifen also have affinity for membrane-bound estrogen receptors. 21 Moreover, GPER mediates the effects of both tamoxifen and raloxifene in endometrial cancer, suggesting activation of membrane-initiated signaling pathways. 22, 23 Therefore, the goals of the current study were to assess the impact of BZA on vascular function; the differences in vascular reactivity between mono and dual hormone therapies; sex differences; and the contribution of GPER. Our overall hypothesis was that BZA would induce greater vascular responses due to activation of GPER.
METHODS

Animals
Male and female wild-type (WT) and GPER knockout (KO) mice (n ¼ 58) were generated and genotyped as previously described. 24, 25 Mice were housed in an AAALACaccredited vivarium with a temperature-controlled 12-hour light-dark cycle. Animals had ad libitum access to standard chow diet and water. All procedures were conducted in accordance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals, and approved and monitored by the Tulane University Institutional Animal Care and Use Committee.
Vascular reactivity
Animals were euthanized using isoflurane, and first-order mesenteric arteries were isolated and removed of surrounding adipose tissue. These resistance vessels were chosen because of their established role in the maintenance of blood pressure. 26 Four vessels from each animal (male WT n ¼ 5, male KO n ¼ 9, female WT n ¼ 8, female KO n ¼ 8) were cut into 2-mm segments and mounted on a wire myograph (DMT 620 M; Danish Myotechnology, Denmark). Internal circumference was normalized to 0.9ÁIC100, where IC100 is the internal circumference at a transmural pressure of 100 mm Hg. 20 Baseline vascular dynamics were assessed in response to 80 mM KCl, 10 À5 M phenylephrine (PE), and 10 À6 M acetylcholine (ACh), and vessels that relaxed less than 50% to ACh were considered denuded and excluded from the study. Three different protocols were used for the study and are illustrated in Supplementary Fig. 1 (http://links.lww. com/MENO/A350).
Protocol 1
Viable vessels were precontracted with prostaglandin F 2a (PGF 2a ; 10 À5 M; Tocris, Bristol, UK) and assigned to receive increasing concentrations of bazedoxifene acetate (BZA; Pfizer, New York, NY), estradiol (E 2 ; Calbiochem, Darmstadt, Germany), or dimethyl sulfoxide (DMSO; 1:5,000 to 1:1,000) as the vehicle. Vessels from the same animal were assigned to different drug treatments, and each vessel was exposed to only one drug for the duration of the study. For the direct vasodilatory effects of these drugs, data were expressed as a % of PGF 2a tension. After repeated 5-minute washings, mesenteric arteries were pretreated for 3 minutes with 10 À9 M BZA, E 2 , or DMSO, and then constricted to increasing concentrations of PE (10 À7 to 10 À4 M). PE contraction curves were expressed as a % of the contraction induced by 80 mM KCl. Vessels were washed and pretreated again for 3 minutes with 10 À9 M BZA, E 2 , or DMSO. After preconstriction with PGF 2a (10 À5 M), the mesenteric arteries were relaxed with increasing concentrations of sodium nitroprusside (SNP; 10 À10 to 10 À5 M). SNP relaxation was expressed as a % of PGF 2a tension.
Protocol 2
A second set of female mice (WT n ¼ 5, KO n ¼ 11) was used to determine vascular reactivity in response to the combination of E 2 with BZA or MPA (Pfizer). Mesenteric arteries were preconstricted to PGF 2a (10 À5 M) and relaxed with increasing concentrations of DMSO, MPA þ E 2 , or BZA þ E 2 (10 À9 to 10 À5.5 M). Vessels were washed and pretreated for 3 minutes with 10 À9 M of the same drugs administered previously: DMSO, MPA þ E 2 , or BZA þ E 2 before being exposed to increasing concentrations of PE (10 À7 to 10 À4 M). Vessels were washed and pretreated again before preconstriction with PGF 2a (10 À5 M) and relaxation with increasing SNP concentrations (10 À10 to 10 À5 M).
Protocol 3
Vascular responses to the GPER agonist G-1 and E 2 were assessed in an additional set of female WT and KO (n ¼ 6 per group) animals. Mesenteric arteries were isolated and preconstricted with PGF 2a (10 À5 M) before relaxing to increasing
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concentrations of E 2 and G-1 (Azano Pharmaceuticals, Albuquerque, NM).
Droplet digital PCR
Tissue was collected from a subset of animals used for vascular reactivity (n ¼ 6-8 per group) to confirm genetic deletion of GPER and potential compensatory changes in ERa. Animals were euthanized using isoflurane, and kidneys were collected and stored in RNAlater solution (ThermoFisher Scientific, Waltham, MA). Harvested tissue (30 mg) was mechanically homogenized in 600 mL of QIAGEN RLT Buffer, and purified RNA was collected via the QIAGEN RNeasy Mini Kit (QIAGEN, Germantown, MD). After droplet generation, onestep reverse transcription was performed with the Bio-rad One-
Step RT-ddPCR Advanced Kit with primers and dual-labeled fluorescent probes for GPER (Assay ID: dMmuCPE5103031) and ERa (Assay ID: dMmuCPE5092740; Bio-rad, Hercules, CA). Droplets were analyzed using the Bio-Rad QX200 system and QuantaSoft software as previously described. 27 
Statistical analysis
All data are presented as mean AE standard error of the mean. A power analysis was completed for each figure using a ¼ 0.05 and 90% power to detect a 20% change in vascular response to confirm the appropriate sample size. Statistical significance for vascular dose-response curves was determined using repeated-measures two-way analysis of variance (ANOVA) (concentration Â treatment), because each vessel was exposed to increasing concentrations of the same drug. ddPCR data were analyzed by two-way ANOVA (sex Â genotype). Statistical tests were followed by Tukey's multiple comparisons and accepted at P < 0.05. Analyses were performed using Prism Version 6.0 software (GraphPad Software Inc, San Diego, CA).
RESULTS
BZA induces greater vasorelaxation than E 2
In mesenteric arteries from male WT animals, both E 2 and BZA significantly relaxed vessels at 10 À5.5 M ( Fig. 1A ; P < 0.001 vs vehicle). Maximum relaxation was significantly greater with BZA (18 AE 8%) compared with E 2 (50 AE 5%; P < 0.001, Cohen's d ¼ 4.9). In female WT vessels, E 2 and BZA induced significant relaxation starting at 10 À6 M ( Fig. 1B ; P ¼ 0.002 and P < 0.001 vs vehicle, respectively). Maximal vasorelaxation was significantly greater for BZA (6 AE 1%) compared with E 2 (37 AE 3%; P < 0.001, Cohen's d ¼ 1.7). Vascular responses to E 2 and BZA were comparable between male and female WT mice (P ¼ 0.818 and P ¼ 0.069, respectively).
Pretreatment with BZA but not E 2 attenuates vasoconstriction
To assess the impact of E 2 and BZA on vasoconstriction, mesenteric arteries were incubated with 10 À9 M BZA, E 2 , or vehicle before increasing concentrations of PE. In male WT arteries, pretreatment with E 2 did not alter the PE response (maximum E 2 : 190 AE 20% vs maximum vehicle: 207 AE 20%; P ¼ 0.81; Fig. 2A ). In contrast, BZA significantly blunted PEinduced vasoconstriction at 10 À6 M and 10 À5 M (P < 0.001 vs vehicle). In female WT arteries, pretreatment with E 2 again failed to alter PE-induced contraction (182 AE 9% vs 171 AE 7%; P ¼ 0.61; Fig. 2B ). However, BZA significantly blunted the PE response up to 10 À4 M PE (64 AE 6%; P < 0.001 vs vehicle, Cohen's d ¼ 4.5). The impact of E 2 on vasoconstriction was comparable between sexes (P ¼ 0.71), but BZA attenuated the PE response to a greater degree in females versus males (P ¼ 0.008).
To assess whether BZA enhanced the smooth muscle response to nitric oxide, male and female WT arteries were pretreated with BZA, E 2 , or vehicle before the SNP relaxation curve. In male WT vessels, the maximal SNP relaxation was comparable between groups (E 2 : 10 AE 1%, BZA: 10 AE 2%, vehicle: 6 AE 1%; P ¼ 0.46; Fig. 2C ). Similar to males, the SNP response in female WT mice was similar (E 2 : 11 AE 1%, BZA: 18 AE 3%, vehicle: 20 AE 4%; P ¼ 0.23; Fig. 2D ).
Dual hormone therapy containing BZA influences vascular reactivity to a greater degree than MPA Clinical treatment of menopausal symptoms combines estrogen with MPA, but a novel alternative is to replace this FIG. 1. Bazedoxifene (BZA) induces greater vasorelaxation than E 2 . Mesenteric artery dilation in response to DMSO, E 2 , or BZA in (A) male and (B) female WT animals. ÃP < 0.05 versus vehicle; # P < 0.05 versus E 2 . DMSO, dimethyl sulfoxide; E 2 , 17b-estradiol; WT, wild-type.
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progestogen with BZA. Therefore, studies were conducted in a separate set of females to assess the impact of these hormone combinations on vascular reactivity. In female WT arteries, both BZA þ E 2 and MPA þ E 2 significantly relaxed vessels starting at 10 À6 M ( Fig. 3A ; P < 0.001 vs vehicle). Maximum dilation was significantly greater for BZA þ E 2 compared with MPA þ E 2 (8 AE 1% vs 31 AE 5%; P < 0.001, respectively).
Additional studies compared the influence of dual hormone therapy on PE-induced contraction and SNP-induced relaxation. Mesenteric arteries were pretreated with BZA þ E 2 , MPA þ E 2 , or vehicle before PE and SNP response curves. PE-induced contraction in female WT mice was similar between pretreated MPA þ E 2 and vehicle ( Fig. 3B ; P ¼ 0.89). However, BZA þ E 2 significantly blunted constriction even at the maximum PE concentration of 10 À4 M (P < 0.001 vs vehicle). In female WT mice, there was a significantly greater SNP response in vessels pretreated with either BZA þ E 2 or MPA þ E 2 ( Fig. 3C ; P < 0.05). In summary, dual hormone therapy with either BZA or MPA enhanced vasorelaxation to SNP, but only therapy containing BZA opposed PE-induced contraction.
GPER deletion confirmed in KO animals
Genomic DNA isolated using tail biopsies was used to genotype animals for use in additional studies (Fig. 4A) . A reduction in GPER function was confirmed by assessing relaxation to the selective agonist G-1 (Fig. 4B) . Vascular responses were only assessed in females due to our previous work showing a reduced response in males.
28 E 2 -induced relaxation was not different between female KO and WT arteries, and the response to E 2 and G-1 was similar in female WT arteries. However, G-1-induced relaxation was significantly blunted in vessels from female KO mice (P ¼ 0.02). Droplet digital PCR was used to confirm a lack of GPER at the mRNA level and to assess potential compensatory up-regulation of ERa due to developmental deletion of GPER. GPER transcript was abolished in kidney samples from both male and female KO mice ( Fig. 4C ; P < 0.001). No alterations in ERa transcript levels were found between WT and KO animals ( Fig. 4D ; P ¼ 0.28). However, renal ERa mRNA was significantly greater in males compared to females in both groups (P < 0.001).
GPER deletion does not alter vascular responses to BZA
Vessels from KO animals were used to determine whether GPER mediates the vascular response to BZA. In male GPER KO mice, both E 2 and BZA significantly relaxed vessels at 10 À6 M ( Fig. 5A ; P ¼ 0.123 and P < 0.001, respectively). Similar to male WT mice, BZA induced a greater maximal relaxation than E 2 (28 AE 11% vs 45 AE 4%; P ¼ 0.005). There were no differences in E 2 and BZA responses between male 
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WT and KO mice (P ¼ 0.64 and P ¼ 0.75, respectively). In female GPER KO animals, vasorelaxation reached statistical significance for BZA starting at 10 À6 M ( Fig. 5B ; P < 0.001), whereas the E 2 response was delayed until 10 À5.5 M (P < 0.001). The maximum dilation was 39 AE 5% for E 2 and 10 AE 4% for BZA (P < 0.001 vs vehicle). There were no differences in E 2 and BZA responses between female WT and KO mice (P ¼ 0.63 and P ¼ 0.43, respectively) Pretreatment with E 2 did not alter PE-induced contraction in male KO mice compared with vehicle ( Fig. 5C ; P ¼ 0.93). In contrast, BZA significantly blunted vasocontraction to 10 À6 M and 10 À5 M PE (P < 0.001 vs vehicle). Maximum constriction to 10 À4 M PE was comparable between E 2 and BZA (160 AE 6% vs 120 AE 19%; P ¼ 0.07), and when compared with vehicle (154 AE 5%; P ¼ 0.93). PE responses for both E 2 and BZA pretreated vessels were similar between male WT and KO mice (P ¼ 0.36 and P ¼ 0.98, respectively). In female GPER KO vessels, pretreatment with E 2 did not alter the PE response (E 2 : 190 AE 9% vs vehicle 176 AE 5%; P ¼ 0.57; Fig. 5D ). Similar to the female WT response, in GPER KO vessels, BZA significantly attenuated vasocontraction even at the maximum PE concentration of 10 À4 M (111 AE 15%; P < 0.001).
Similar to WT vessels, the SNP response in male GPER KO vessels was not altered between treatment groups (E 2 : 11 AE 3%, BZA: 11 AE 2%, vehicle: 12 AE 3%; P ¼ 0.91; Fig. 5E ). SNP responses in the presence of E 2 and BZA were similar between male WT and KO mice (P ¼ 0.97 and P ¼ 0.93, respectively). The SNP response in female GPER KO vessels was not altered by treatment (E 2 : 16 AE 6%, BZA: 11 AE 2%, vehicle: 16 AE 7%; P ¼ 0.43; Fig. 5F ). The SNP response between female WT and GPER KO mice was similar for E 2 pretreated vessels (P ¼ 0.97). However, the SNP response was greater in GPER KO vessels pretreated with BZA compared with WT females (P ¼ 0.006).
GPER deletion does not alter BZA response in dual hormone treatment
Female GPER KO mice were used to determine the contribution of GPER in the effects of dual hormone therapies using BZA and MPA. Both BZA þ E 2 and MPA þ E 2 significantly relaxed preconstricted vessels in female GPER KO mice starting at 10 -6 M ( Fig. 6A ; P < 0.001 vs vehicle). Maximum dilation was significantly greater for BZA þ E 2 compared with MPA þ E 2 in KO vessels (9 AE 3% vs 25 AE 5%; P < 0.001). The direct vasodilatory response of BZA þ E 2 and MPA þ E 2 was not altered when GPER was deleted (P ¼ 0.098 and P ¼ 0.40 vs WT, respectively). Vasoconstriction to PE in female GPER KO animals was significantly blunted by pretreatment with BZA þ E 2 ( Fig. 6B ; P < 0.001 
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vs vehicle), but not by MPA þ E 2 (P ¼ 0.4805 vs vehicle). Maximum constriction to PE was significantly different between pretreatment with BZA þ E 2 (73 AE 19%) and MPA þ E 2 (175 AE 7%; P < 0.001). GPER deletion did not alter the PE response in vessels pretreated with BZA þ E 2 and MPA þ E 2 (P ¼ 0.91 and P ¼ 0.50 vs WT, respectively). Female GPER KO artery responses to SNP were similar between treatment groups (BZA þ E 2 : 12AE 3%, MPA þ E 2 : 12 AE 5%, vehicle 14 AE 10%; P ¼ 0.89; Fig. 6C ). GPER deletion did not alter the SNP response in vessels pretreated with BZA þ E 2 and MPA þ E 2 (P ¼ 0.78 and P ¼ 0.62 vs WT, respectively).
DISCUSSION
The major finding from the current study is that BZA is a more potent vasodilator than E 2 , and unlike E 2 , also opposes PE-induced contraction. In addition, we showed that the combination of BZA þ E 2 induced greater responses than MPA þ E 2 in the mesenteric arteries of female mice. The impact of BZA on vascular reactivity was mostly independent of sex, and was not altered by genetic deletion of GPER. These results indicate a potential for enhanced vasoprotection for dual hormone therapies using BZA compared with MPA.
Bazedoxifene was a more potent vasodilator than E 2 in mesenteric arteries even though its binding affinity to ERa/ ERb is lower. 29, 30 Moreover, BZA and BZA þ E 2 , but not E 2 or MPA þ E 2 , significantly blunted PE-induced contraction. In cerebral arteries of male rabbits, BZA prevents vasocontraction via inhibition of L-type Ca 2þ channels. 31 A potential mechanism is estrogen-induced translocation of these ion channels from the membrane to the nucleus, resulting in lower plasma membrane localization in female versus male C57Bl/6J mice. 32 However, we did not observe a sex difference in PE-induced contraction in the current study. Loss of circulating estrogen during this ex vivo approach could disrupt the translocation of L-type Ca 2þ channels and promote a similar phenotype in males and females. BZA may be more effective than E 2 in reducing the number of membrane-bound L-type Ca 2þ channels to blunt PE-induced contraction. Vasorelaxation to the nitric oxide donor SNP was not altered by E 2 or BZA, but was enhanced by dual treatment containing BZA þ E 2 or MPA þ E 2 , indicating a cooperative or synergistic mechanism. Similarly, the combination of E 2 and progesterone, but neither alone, promotes an increase in the SNP response in cerebral slices from female Sprague- 
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Dawley rats. 33 Progesterone also augments the response to SNP in myometrial smooth muscle. 34 However, in canine coronary arteries 35 and premenopausal women, 36 progesterone antagonizes the vasodilatory effects of estradiol. The possibility that MPA attenuates the protective effects of estrogen is often considered when reflecting on the failure of the WHI trials, 37 and clinical studies using natural progesterone formulations will hopefully provide additional 
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information. 38 However, neither our study nor data from postmenopausal women indicates a detrimental effect of MPA on smooth muscle-mediated vasorelaxation. 39 We did not assess endothelium-dependent relaxation in the current study because responses to raloxifene are independent of the endothelium and nitric oxide. 40, 41 Moreover, the vasodilatory effect of BZA in rabbit basilar arteries is not impacted by denuding, inhibition of nitric oxide synthase, or cyclooxygenase inhibition. 31 While this study suggests that the mechanism for BZA's effects include opening of potassium channels, a high potassium buffer or potassium channel inhibitors attenuate the vasodilatory response by only 20% to 25%. However, our data are similar to this study when considering the impact of BZA on L-type calcium channels. In our hands, BZA significantly attenuated and, in some cases, abolished the response to phenylephrine, suggesting a significant impact on extracellular calcium entry. Future studies should look more closely at the impact of BZA on calcium mobilization using fluorescent imaging techniques.
We did not observe a sex difference in either E 2 or BZAinduced dilation in the mesenteric arteries, but the ability of BZA to blunt PE-induced contraction was greater in females compared with males. Other studies show that E 2 -mediated vasorelaxation is greater in female ERa knockout aortas 42 and mesenteric arteries from female mRen2 rats. 28 In addition, female Sprague-Dawley rats have reduced raloxifene-induced dilation in pulmonary veins, 43 but greater dilation in mesenteric arteries. 44 We also found that males have greater renal ERa mRNA and similar GPER levels compared with females. Our results parallel those in mice showing greater renal ERa transcript in adult males, but greater protein expression in females. 45 Future studies are aimed at profiling sex differences in estrogen receptor expression in all cardiovascular tissues. Overall, these results indicate that the vascular benefits of BZA may be applicable to both sexes, providing additional options for treating cardiovascular complications.
We have previously shown the importance of GPER in vascular function 16 and remodeling, 46 and SERMs activate GPER in endometrial tumor cells, 23 monkey kidney fibroblasts, 47 and cerebral arteries from male rabbits. 31 Therefore, we hypothesized that the protective vascular effects of BZA were mediated by GPER. However, our results show that the vascular response to BZA was independent of this receptor in both males and females. Interestingly, genetic deletion of GPER also failed to alter the vasodilatory response to E 2 , despite attenuation of the response to the selective GPER agonist. Some overlap may exist in the pathways by which E 2 induces vascular effects, resulting in a lack of phenotype when removing one estrogen receptor. Similarly, in male aortas, selective activation of GPER induces the same 
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vasodilation as nonselective E 2 , but when GPER is deleted the E 2 response is attenuated, but not abolished. 18 Receptor compensation may also occur in response to germline deletion, and studies from ERa, ERß, and double ER knockout mice provide evidence that this compensation occurs when deleting the nuclear estrogen receptors. 48 While we found no evidence of renal ERa up-regulation in the absence of GPER, nuclear ERs may have the capacity to functionally compensate for GPER in its absence. Alternatively, BZA may activate an estrogen receptor-independent pathway, which was not altered in GPER KO mice. The recruitment of additional pathways in parallel with ERs may account for the disparity in vasodilation between E 2 and BZA, and provide a mechanism by which BZA opposes PE-induced contraction. Moreover, these results indicate a potential for enhanced vasoprotection for dual hormone therapies using BZA compared with MPA.
Because current menopausal hormone treatments using BZA produce circulating concentrations of approximately 6 nM, 49 one limitation to our study is the use of micromolar concentrations to induce ex vivo vasodilation. This discrepancy is also observed for E 2 -induced ex vivo vasodilation, [50] [51] [52] [53] and most likely results from supraphysiological preconstriction of arteries to maintain tone during a concentration response curve. In contrast, our results showing that 1 nM BZA and BZA þ E 2 , but not E 2 or MPA þ E 2 , opposed PEinduced contraction may more precisely reflect the in vivo environment. A second limitation of the current study is the measurement of acute but not chronic vascular response to BZA. Since BZA down-regulates ERa, 54 the impact of longterm BZA on vascular function remains to be determined. Cardiovascular safety is a primary concern for menopausal hormone therapy, and SERMs may increase the risk for stroke and venous thromboembolism. 55, 56 However, these events were considered within acceptable safety profile and should be weighed against the benefits.
CONCLUSIONS
The current study showed that BZA had more potent vasodilatory properties than E 2 in resistance vessels of both sexes independently of GPER. BZA has beneficial effects on bone, lipid metabolism, and uterine and breast tissue, 56, 57 and our study indicates additional benefits in the vasculature. Overall, the findings in the current study support that dual hormone therapy containing BZA may provide vascular benefits over therapies containing MPA.
Potential clinical value
In the current study, we showed that BZA has enhanced vascular benefits in murine mesenteric arteries compared with E 2 and MPA. These findings indicate that clinical administration of dual hormone therapy containing BZA may offer vascular protection than therapies containing MPA. Despite seeing enhanced vascular benefits in the current study, caution remains with hormone therapies containing SERMs due to the increased risk of venous thromboembolic events. 56, 58 Therefore, further studies need to assess the long-term implications of hormone therapy containing BZA on the cardiovascular system.
